Federated Hermes’s Dianthus Therapeutics DNTH Stock Holding History

Federated Hermes’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.35M	Buy	+13,823	New	+$1.21M	﹤0.01%	1084
2022 Q3	–	Sell	-11,832	Closed	-$227K	–	2160
2022 Q2	$227K	Sell	11,832 -12,380	-51%	-$306K	﹤0.01%	1514
2022 Q1	$1.12M	Buy	24,212 +8,392	+53%	+$458K	﹤0.01%	1204
2021 Q4	$1.12M	Buy	15,820 +2,273	+17%	+$228K	﹤0.01%	1233
2021 Q3	$1.58M	Sell	13,547 -52	-0.4%	-$6.06K	﹤0.01%	1117
2021 Q2	$2.13M	Buy	13,599 +7,268	+115%	+$1.34M	﹤0.01%	1076
2021 Q1	$1.2M	Buy	6,331 +6,038	+2,061%	+$1.02M	﹤0.01%	1303
2020 Q4	$37K	Buy	293 +26	+10%	+$2.95K	﹤0.01%	1848
2020 Q3	$29K	Hold	267	–	–	﹤0.01%	1851
2020 Q2	$32K	Sell	267 -16	-6%	-$2.25K	﹤0.01%	1815
2020 Q1	$28K	Sell	283 -14	-5%	-$2.59K	﹤0.01%	1753
2019 Q4	$72K	Sell	297 -68	-19%	-$12.7K	﹤0.01%	1707
2019 Q3	$60K	Buy	365 +133	+57%	+$25.3K	﹤0.01%	1704
2019 Q2	$55K	Buy	+232	New	+$57.4K	﹤0.01%	1663

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Federated Hermes's DNTH Position: Q2 2026 in Review

Federated Hermes opened a new position in Dianthus Therapeutics (DNTH) in Q2 2026: 13,823 shares worth $1.35M. The stake represents ﹤0.01% of the portfolio and ranks #1084 among its holdings. This is a return to the name: Federated Hermes previously reported a position in DNTH as recently as Q2 2022.

Federated Hermes first reported a position in DNTH in Q2 2019 and has held it in 14 quarters since. The position peaked at $2.13M in Q2 2021. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

Federated Hermes held 13,823 shares of Dianthus Therapeutics worth $1.35M as of Q2 2026.
Dianthus Therapeutics was a new Federated Hermes position in Q2 2026.
Dianthus Therapeutics made up ﹤0.01% of Federated Hermes's portfolio in Q2 2026, its #1084 holding.
Federated Hermes first reported a position in Dianthus Therapeutics in Q2 2019 and has held it in 14 quarters since.
Federated Hermes's Dianthus Therapeutics position peaked at $2.13M in Q2 2021.
270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.